Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02802982 · ClinicalTrials.gov registry record
Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
A clinical trial of Neonatal Thrombocytopenia, sponsored by Boston Children's Hospital.
- Active
- Registry status
- 28
- Enrollment target
- 3
- Study locations
NCT02802982: Active study of Neonatal Thrombocytopenia, sponsored by Boston Children's Hospital.
NCT02802982 is a study of Neonatal Thrombocytopenia that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 28 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02802982, a study of Neonatal Thrombocytopenia, is active but no longer recruiting, sponsored by Boston Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
Parents of infants who have been thrombocytopenic for 3-4 days will be approached for consent to enter the study. For the purposes of the study, thrombocytopenia will be defined as a platelet count \<60,000/uL or a platelet count \<100,000/uL that prompted a platelet transfusion. Following enrollment, the platelet count will be followed in each infant. Participants will enter the study if on day 5 or later after the onset of thrombocytopenia (defined as above) infants either have a platelet count \<60,000/uL or a platelet count \<100,000/uL for which a platelet transfusion is ordered.
Conditions Studied
Study Locations (3)
Massachusetts
- Boston Children's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-04 |
| Est. Completion | 2024-12 |
What the registry record for NCT02802982 still lists
NCT02802982 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 1 condition, with Neonatal Thrombocytopenia appearing as the primary indexed condition, and to 0 interventions.
NCT02802982 reports a single indexed study location in Massachusetts, Iowa.
Frequently Asked Questions
What is clinical trial NCT02802982 about?
NCT02802982 is a clinical study titled "Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates". Parents of infants who have been thrombocytopenic for 3-4 days will be approached for consent to enter the study. For the purposes of the study, thrombocytopenia will be defined as a platelet count \<60,000/uL or a platelet count \<100,000/uL that prompted a platelet transfusion. Following enrollmen...
What is the current status of trial NCT02802982?
This trial is currently active not recruiting. The enrollment target is 28 participants. The study started on 2013-04. Estimated completion is 2024-12.
What conditions does trial NCT02802982 study?
This clinical trial studies the following conditions: Neonatal Thrombocytopenia.
Who is sponsoring clinical trial NCT02802982?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02802982 being conducted?
This trial has 3 study locations across Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia